Antithrombotic therapy in end-stage renal disease

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Antiplatelet and antithrombotic agents have established risk-benefit profiles in the general population.
• Use in end-stage renal disease (ESRD) presents unique challenges due to a prothrombotic state and high bleeding risk.
• Limited clinical trials and evidence exist for antithrombotic drug safety and efficacy in advanced chronic kidney disease.

Purpose of the Study:

• To review the benefits and risks of antiplatelet and antithrombotic agents for cardiovascular event prevention in ESRD patients.
• To evaluate anticoagulation risks for stroke prevention in nonvalvular atrial fibrillation within the ESRD population.
• To explore the potential role of newer oral anticoagulants in dialysis patients.

Main Methods:

• Literature review and synthesis of existing clinical trial data.
• Analysis of risk-benefit profiles for antiplatelet and antithrombotic therapies.
• Evaluation of evidence regarding anticoagulation for stroke prevention in ESRD.

Main Results:

• The decision to use antithrombotic agents in ESRD requires individualized assessment due to complex risk factors.
• There is a significant lack of robust clinical evidence guiding antithrombotic therapy in this population.
• Routine anticoagulation for stroke prevention in nonvalvular atrial fibrillation in ESRD carries substantial bleeding risks.

Conclusions:

• Therapeutic decisions for antiplatelet and antithrombotic agents in ESRD must be highly individualized.
• Further research is critically needed to establish safe and effective antithrombotic strategies for ESRD patients.
• Newer oral anticoagulants may offer alternative options but require careful consideration in the dialysis population.